Cancer Drug Parity Act of 2026 ensures cost-sharing for oral anticancer drugs is no less favorable than for injectable drugs.

The Cancer Drug Parity Act of 2026 amends the Employee Retirement Income Security Act of 1974 to require group health plans to provide cost-sharing for oral anticancer drugs on terms no less favorable than those for injectable drugs. It prohibits plans from imposing higher out-of-pocket costs or more restrictive limitations on oral drugs. The Act also mandates a study on the impact of these provisions and prohibits plans from requiring prior authorization or imposing other controls for anticancer medications. The changes apply to plan years beginning on or after January 1, 2027.

Cancer Drug Parity Act of 2026 ensures cost-sharing for oral anticancer drugs is no less favorable than for injectable drugs.

The Cancer Drug Parity Act of 2026 amends the Employee Retirement Income Security Act of 1974 to require group health plans to provide cost-sharing for oral anticancer drugs on terms no less favorable than those for injectable drugs. It prohibits plans from imposing higher out-of-pocket costs or more restrictive limitations on oral drugs. The Act also mandates a study on the impact of these provisions and prohibits plans from requiring prior authorization or imposing other controls for anticancer medications. The changes apply to plan years beginning on or after January 1, 2027.